Research Blog
Evidence-based articles on peptide mechanisms, dosing protocols, clinical data, and research methodology. Cited sources. No hype.
IGF-1 vs IGF-1 LR3: Why the Modified Version Lasts Twelve Times Longer
IGF-1 LR3 was engineered to escape the binding proteins that suppress native IGF-1 in serum. The modification is a 13-residue extension and an arginine substitution. Here is what those two changes do and why the cell-culture and in vivo data look different than they do for the native peptide.
CJC-1295 With vs. Without DAC: Pharmacokinetics, Half-Life, and What Matters for Research
CJC-1295 with DAC has a half-life of 5.8–8.1 days; the no-DAC version clears in 20–30 minutes. A data-grounded breakdown of what those numbers mean for GH pulsatility and research protocol design.
The CJC-1295 + Ipamorelin Stack: Research Rationale and Synergy Data
CJC-1295 and Ipamorelin target different receptor systems — GHRH receptors and GHS-R1a respectively — creating synergistic GH pulses that exceed either compound alone. A mechanistic breakdown of why the combination works.
AOD 9604 Research: What 900 Clinical Trial Participants Taught Us About This GH Fragment
AOD 9604 went through multiple human clinical trials enrolling 900+ participants before Metabolic Pharmaceuticals discontinued it in 2007. The story of what those trials found — and why the compound failed commercially despite real efficacy signals — is one of the most instructive in peptide research.
Growth Hormone Secretagogues Explained: The Researcher's Guide to GHRH and GHRP Peptides
GHRH analogs like CJC-1295 and ghrelin mimetics like Ipamorelin work through distinct pathways to stimulate the body's own GH production — a fundamentally different approach from exogenous growth hormone. Here's the endocrinology behind how they work.